{'fraction_non_alphanumeric': 0.021739130434782608, 'fraction_numerical': 0.007246376811594203, 'mean_word_length': 5.4865771812080535, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
How safe is diode laser peripheral iridoplasty for the corneal endothelium?

inhibitors on IOP in both open and narrow angle glaucoma have been well described in the literature. However, this is the first reported case where a serotonin and noradrenaline reuptake inhibitor resulted in a dramatic effect on IOP in a patient with open angle glaucoma. In the nervous system, serotonin is synthesized in neurons and stored in vesicles. Activation of postsynaptic serotonergic (5-HT) receptors mediate a wide range of physiological functions with seven different families of 5-HT receptors and their subpopulations identified. The presence of serotonin and its metabolites (5-hydroxyindolacetic acid and 5-hydroxytrypophol) in aqueous, alongwith 5-HTreceptors in the iris ciliarybodycomplex, suggest serotonin may have a role in IOP regulation. Direct activation of 5-HT7 receptions has been shown to increase aqueous production via a rise in cyclic adenosine monophosphate levels, and stimulation of 5-HT2A/2C receptors in the ciliary body indirectly enhance ciliarybodybloodflow, thuspromoting theproduction of aqueous by the ciliary processes. The effect of 5-HT2 receptor agonism has not yet fully been investigated in humans; however, the administration of topical ketanserin, a selective 5-HT2A receptor antagonist, has been shown to reduce IOP inbothhuman and animalmodels. In healthy eyes, the serotonergic effect of increased aqueous production is matched by corresponding increase in aqueous outflow. However, when autoregulation is impaired or when outflow resistance is increased, as occurs in open angle glaucoma, a rise in IOPmay be observed. Venlafaxine may cause an idiosyncratic increase in IOP in patients with primary open angle glaucoma. Awareness that IOP may rise precipitously needs to be increased, for clinicians prescribing venlafaxine, as well as those managing patients with glaucoma and ocular hypertension.